Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs StandardAero Inc. Common Stock (SARO) Price & Performance

Eli Lilly And CoTrade
StandardAero Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs StandardAero Inc. Common Stock — how do they compare? Eli Lilly And Co trades at $1,213.51 (market cap $1.04T), while StandardAero Inc. Common Stock trades at $19.73 (market cap $6.58B). The key difference: Eli Lilly And Co is far larger — about 158.1× StandardAero Inc. Common Stock's market cap, and Eli Lilly And Co pays a 0.59% dividend while StandardAero Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 94 Days and StandardAero Inc. Common Stock for 0 Days on average.

LLYSARO
Market Cap
$1.04T$6.58B
Volume
1,843,3753,663,186
Sector
HealthIndustrials
52-Week High
$1.28K$33.12
52-Week Low
$799.57$19.76
Typical Hold Time
94 Days0 Days
Enterprise Value
$1.09T$8.96B
Dividend Yield
0.59%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,211.40, up 2.43% today, with a bullish technical outlook and strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 surpassing the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights pipeline advancements in weight-loss drugs, including EloraTZP's promising trial results.

Outlook remains positive given dominant market position in obesity and diabetes treatments, with analyst consensus price target of $1,350 implying ~11% upside. Key risks include competitive pressures from Novo Nordisk and regulatory hurdles. Earnings growth and pipeline catalysts support further appreciation, though high valuations warrant monitoring.

StandardAero Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LLY
20% Buy80% Sell
Avg holding period · 94 Days
SARO
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY →

About StandardAero Inc. Common Stock

StandardAero, Inc. is an independent provider of aircraft engine maintenance, repair, and overhaul services, supporting commercial, military, and business aviation customers across more than 40 engine platforms.

Read more on SARO →